Innovations In Gene Therapy: Building The Complete Solution For Viral Vector Production

Scaling and accelerating viral vector production from research to commercialization

Adeno-associated virus (AAV) is rapidly becoming the go-to biological delivery method for the latest gene therapy breakthroughs; more than 1,300 unique gene therapy products are currently under development and nearly half are reliant on AAV. Thus, the ability to scale production of these impactful therapies is critical to bringing down costs and accelerating the process from research to commercialization.

Tune into this webinar and learn about:

• The broad range of products and technologies available in the gene therapy field
• The Gibco AAV-MAX™ Helper-Free AAV production system for producing high titer AAV, as well as the associated upstream technologies for scale up, downstream technologies for virus purification, and analytical tools for product characterization
• Flexible solutions for clinical and commercial scale viral vector production
• Process diversity and scale-up challenges in upstream processes